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Huntington’s disease (HD) is one of a group of neurodegenerative disorders caused by the pathological
expansion of a glutamine tract. A hallmark of these so-called polyglutamine diseases is the presence of ubi-
quitylated inclusion bodies, which sequester various components of the 19S and 20S proteasomes. In
addition, the ubiquitin–proteasome system (UPS) has been shown to be severely impaired in vitro in cells
overexpressing mutant huntingtin. Thus, because of its fundamental housekeeping function, impairment
of the UPS in neurons could contribute to neurotoxicity. We have recently proposed that the proteasome acti-
vator REGg could contribute to UPS impairment in polyglutamine diseases by suppressing the proteasomal
catalytic sites responsible for cleaving Gln–Gln bonds. Capping of proteasomes with REGg could therefore
contribute to a potential ‘clogging’ of the proteasome by pathogenic polyglutamines. We show here that gen-
etic reduction of REGg has no effect on the well-defined neurological phenotype of R6/2 HD mice and does
not affect inclusion body formation in the R6/2 brain. Surprisingly, we observe increased proteasomal
‘chymotrypsin-like’ activity in 13-week-old R6/2 brains relative to non-R6/2, irrespective of REGg levels.
However, assays of 26S proteasome activity in mouse brain extracts reveal no difference in proteolytic
activity regardless of R6/2 or REGg genotype. These findings suggest that REGg is not a viable therapeutic
target in polyglutamine disease and that overall proteasome function is not impaired by trapped mutant poly-
glutamine in R6/2 mice.
INTRODUCTION
Huntington’s disease (HD) belongs to a devastating group of
neurodegenerative diseases caused by the pathogenic expan-
sion of a CAG trinucleotide within the disease gene. These
polyglutamine diseases include spinal and bulbar muscular
atrophy (SBMA), dentatorubral pallidoluysian atrophy and
spinocerebellar ataxia types 1, 2, 3, 6, 7 and 17. For most
of the polyglutamine diseases, there exists a sharp threshold
for disease. In HD, individuals with repeats of 35 or less
will remain unaffected, whereas in those patients with 40 or
more repeats, the disease will manifest in a normal lifetime.
A common pathogenic marker in HD and other polygluta-
mine diseases is the presence of proteinaceous aggregates
which can culminate as an inclusion body inside or outside
of neuronal nuclei. These inclusions are present in HD
mouse (1) and human brains (2), although their pathological
significance is widely debated. Evidence that the aggregation
process is dependent on a pathogenic polyglutamine length
is incontrovertible (3), and directing pre-formed polyglutamine
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inclusions to the nucleus is toxic to the cell (4). However,
the possibility that inclusion body formation is controlled in
the neuron as a cytoprotective response could mean that the
mere presence of an inclusion body is not necessarily as patho-
genic as the presence of soluble mutant polyglutamine or
smaller oligomeric aggregates (5–7).
The ubiquitin–proteasome system (UPS) is an essential part
of cellular housekeeping, which degrades proteins that are
tagged with four or more ubiquitin monomers. The fact that
inclusion bodies are polyubiquitylated suggests that the UPS
has made futile attempts to degrade components of the
inclusion. Indeed, once polyglutamine proteins have aggre-
gated in an inclusion, they are resistant to degradation by
the UPS (8). The UPS is further implicated in polyglutamine
pathogenesis by the fact that various components of the 26S
proteasome are sequestered to inclusions, suggesting that the
UPS may be actively engaged in an attempt to degrade com-
ponents of the inclusions (9,10). Direct evidence of UPS
dysfunction in polyglutamine disease came from a cell
model overexpressing mutant huntingtin, where a dramatic
accumulation of a GFP-based UPS reporter containing the
CL-1 degron was observed (11,12). Although this effect has
also been observed in an ataxin-1 cell model (13), no impair-
ment was observed in an HD cell model expressing a UPS
reporter with an N-end rule or a ubiquitin fusion degradation
(UFD) signal (8).
It is currently unknown how the UPS is involved in the
pathogenesis of polyglutamine disease in vivo. Recent evi-
dence from an SCA7 mouse model shows that polyglutamine
pathogenesis can occur in photoreceptor cells in the absence of
any significant UPS impairment, as detected by a UFD-based
reporter (14). In addition, no impairment in core proteasome
activity was found in HdhCAG150 knock-in mouse brains
(15), whereas HD94 conditional mice show an upregulation
in this activity (16). However, in human HD brain and fibro-
blasts, a diminution in core proteasome activity has been
described, evidence of a proteasome disturbance in sympto-
matic patients (17).
There is strong evidence that proteins with a mutant poly-
glutamine tract are intrinsically difficult to degrade (18,19).
Indeed, more recent data suggest that polyglutamine tracts
are not degraded at all by eukaryotic proteasomes (20).
However, it has also been shown that cells expressing
mutant polyglutamines directed to the UPS show reduced
inclusion formation (21,22). This suggests that although poly-
glutamine tracts are intrinsically difficult to degrade, directing
them to the UPS is still overall sufficient to increase their
degradation.
We have recently hypothesized that the nuclear proteasome
activator REGg may be contributing to polyglutamine patho-
genesis, largely due to our in vitro data which suggest that it
can inhibit proteasomal cleavage between Gln–Gln bonds
and the fact that it is enriched in the brain (23,24). REGg
binds to the 20S proteasome as a doughnut-shaped homo-
heptamer and alters the cleavage specificity of the three-core
proteasome active sites. We have shown that REGg activates
the trypsin-like active site in vitro, but suppresses the
chymotrypsin-like and peptidyl–glutamyl preferring hydro-
lytic (PGPH) active sites, which are responsible for cleaving
Gln–Gln bonds (23). Furthermore, a REGg mutant (K118E)
is capable of activating all three catalytic activities and
promoting cleavage after glutamines (24). Thus, we have pro-
posed that mutant polyglutamines may become kinetically
trapped in proteasomes capped with REGg causing ‘clogging’
of proteasomes and contributing to neurotoxicity. We have
tested this hypothesis in vivo by crossing REGg-deficient
mice to R6/2 HD mice. REGg KO mice have been generated
previously and are viable, but slightly growth impaired (25).
We found that the genetic reduction of REGg did not alleviate
the neurological phenotype of R6/2 mice and did not alter
inclusion body formation in the R6/2 brain. In addition, we
report that ‘chymotrypsin-like’ proteasome activity is upregu-
lated in the R6/2 brain regardless of REGg levels, whereas
there is no change in 26S proteasome activity. Our results
suggest that REGg is not involved in polyglutamine disease
and that there is no net proteasome impairment in the R6/2
mouse brain as a result of trapped mutant polyglutamine.
RESULTS
REGg protein levels are unchanged in R6/2 brains
and absent in nulls
A common feature of polyglutamine disease is transcriptional
dysregulation, resulting in altered levels of affected proteins.
Indeed, neurons may even attempt to upregulate or downregu-
late certain genes as a response to disease progression. There-
fore, before determining the effect of reducing REGg protein
levels on the well-defined neurological phenotype of R6/2, it
was important to establish that basic REGg levels were unal-
tered in the R6/2 brain as a result of the disease process.
Western blot analysis and subsequent phosphorimager quanti-
fication revealed that REGg levels were similar in brain
lysates of 12-week-old R6/2 compared to that of wild-type
(WT) (Fig. 1A). Next, to ensure that protein levels of REGg
were reduced as expected in heterozygous and null mice,
western blot analysis was applied to brain lysates. Levels of
REGg were found to be approximately halved in heterozy-
gotes and completely absent in null mice as expected
(Fig. 1B). We also sought to determine whether the genetic
reduction of REGg would cause an alteration in the protein
expression of REGa, a homologue of REGg. We found that
REGa levels were unaltered by the reduction of REGg
(Fig. 1B). This is in good agreement with Murata et al. (25),
who found that REGa expression was unchanged in REGg-
deficient mouse embryonic fibroblasts. In addition, they
reported no change in the cytoplasmic localization of REGa,
suggesting that it does not enter the nucleus to compensate
for the REGg deficiency.
REGg is located in neuronal nuclei in both WT and
R6/2 mice
Central to the hypothesis that REGg-capped proteasomes con-
tribute to polyglutamine pathogenesis is the localization of
REGg to the nucleus, a major site of inclusion body formation
and pathogenesis in polyglutamine disease. Previous work has
demonstrated a predominant nuclear localization of REGg in
neuronal cell lines (26), Drosophila embryos (27) and cultured
mouse embryonic fibroblasts (25). To confirm localization of
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REGg in the mouse brain, immunohistochemistry was per-
formed on coronal sections. REGg was found to be highly
expressed and has a nuclear localization throughout the
mouse brain. A representative image from mouse cortex is
shown in Figure 2A. The lack of any specific staining in
REGg null mice confirms that the protein is absent in these
mice and that the antibody is specific (Fig. 2A). To confirm
the subcellular localization of REGg biochemically, western
blot analysis was performed on 12-week-old nuclear and cyto-
plasmic brain fractions. It is clear that REGg is present only in
the nuclear fraction and that its subcellular location is unal-
tered in the R6/2 brain (Fig. 2B). Finally, to distinguish
between the possibility that REGg is expressed in neurons
or glia, colocalization studies were carried out between the
REGg and the neuronal marker NeuN. We found that REGg
is expressed mainly in neurons and little, if any, was detected
outside of neurons. A representative image from WT mouse
cortex can be seen in Figure 2C.
Reduction of REGg does not affect the behavioural
phenotype of R6/2 mice
Once we had confirmed that REGg is located in mouse neur-
onal nuclei and that protein levels are efficiently reduced in
heterozygous and null mice, it was possible to cross REGg-
deficient mice to R6/2 and investigate the effect of REGg
reduction on R6/2 neurological behaviour. Five-week-old
R6/2 males were crossed to heterozygous REGg females
to generate males of the genotype R6/2; REGgn/þ (n ¼ null
allele). These males were then backcrossed to REGgn/þ
females to generate six possible genotypes: REGgþ/þ,
REGgn/þ or REGgn/n on an R6/2 or non-R6/2 background.
The CAG repeat size of the R6/2 mice was well matched.
CAG repeat means were as follows: R6/2 ¼ 222.5; R6/2;
REGgn/þ ¼ 224.3; R6 and REGgn/n ¼ 223.5. Ten to 15
females of each genotype were divided equally between
cages to ensure a variety of genotypes from different litters
were present in each cage. The mice were tested for rotarod
performance, grip strength and exploratory activity, and their
weight was monitored weekly.
Rotarod is a sensitive test of motor coordination and balance,
and R6/2 mice have been previously shown to have impaired
rotarod performance from 6 weeks (28,29). We found
that R6/2 mice performed significantly worse on rotarod
than non-R6/2 mice at all timepoints tested (Fig. 3A). For
example, at 12 weeks, R6/2 performed significantly worse
than non-R6/2 [General Linear Model (GLM) ANOVA:
F(1,59) ¼ 50.2, P , 0.001]. The genetic reduction of REGg
did not affect the impairment in R6/2 performance at any time-
point, e.g. there was no interaction between R6/2 and REGg
genotypes at 12 weeks (GLM ANOVA: F(2,58) ¼ 0.97,
P ¼ 0.386). Interestingly, REGgn/n mice performed signifi-
cantly worse than REGgþ/þ or REGgn/þ at 4 weeks (post
hoc analysis: T ¼ 2.812, P ¼ 0.0181 and T ¼ 3.737,
P ¼ 0.0012, respectively), whether or not they expressed the
R6/2 transgene [no interaction between REGg and R6/2 geno-
types (GLM ANOVA: F(2,58) ¼ 0.12, P ¼ 0.889)]. REGgn/n
mice were also significantly worse than REGgþ/þ at 8 weeks
(post hoc analysis: T ¼ 3.055, P ¼ 0.0093), but not signifi-
cantly different from REGgn/þ (post hoc analysis: T ¼ 2.158,
P ¼ 0.0871). By 10 weeks, there was no significant difference
between the REGg genotypes (GLM ANOVA: F(2,58) ¼ 0.22,
P ¼ 0.803) or at 12 weeks (GLM ANOVA: F(2,58) ¼ 0.22,
P ¼ 0.802), suggesting that the rotarod impairment in REGg
nulls is present only at a young age and could possibly be
attributed to retarded growth (Fig. 3D).
Grip strength analysis showed that R6/2 mice had a sig-
nificantly weaker grip than non-R6/2 by 12 weeks (GLM
ANOVA: F(1,59) ¼ 49.57, P , 0.001) (Fig. 3B) and this was
regardless of REGg genotype [no interaction between
R6/2 and REGg genotypes at 12 weeks (GLM ANOVA:
F(2,58) ¼ 0.33, P ¼ 0.717)]. In addition, although R6/2 mice
gain significantly less weight than non-R6/2 mice (12 weeks
GLM ANOVA: F(1,59) ¼ 4.59, P ¼ 0.036) (Fig. 3C), REGg
genotype has no effect on this failure to gain weight
Figure 1. Protein levels of REGg and REGa in mouse brain. (A) REGg levels
are unaltered in 12-week R6/2 brains, as shown by western blot and phosphoi-
mager quantification with respect to a-tubulin. Error bars show the standard
error of the mean (Student’s t-test, P ¼ 0.419). (B) REGg levels are halved
in heterozygous mice and absent in null mice as expected. REGa levels are
unaltered by the loss of REGg. b-actin was used as a loading control. n,
null allele.
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(no interaction at 12 weeks, GLM ANOVA: F(2,58) ¼ 0.09,
P ¼ 0.918). We also observed that REGgn/n mice weighed sig-
nificantly less than heterozygous or WT mice until 8 weeks
(e.g. GLM ANOVA: F(2,58) ¼ 3.55, P ¼ 0.035 for 8 weeks),
but this effect was gone by 9 weeks (GLM ANOVA:
F(2,58) ¼ 2.93, P ¼ 0.061) (Fig. 3D). This is consistent with
the growth deficits of REGg null mice observed previously
(25), and interestingly, the effect is lost at approximately the
same age as the disappearance of rotarod impairment in
REGg null mice, supporting a role for REGg in post-natal
mouse development.
Exploratory activity revealed an overall hypoactivity of
R6/2 mice compared with non-R6/2 mice at 13 weeks,
where P-values were less than 0.004 for all parameters
tested (Fig. 4). For most parameters tested, REGg had no
effect on R6/2 hypoactivity, although there was a significant
negative interaction between R6/2 and REGg genotypes
for activity and rearing (GLM ANOVA: F(2,58) ¼ 3.31,
P ¼ 0.043 and F(2,58) ¼ 3.79, P ¼ 0.029, respectively).
REGg did not affect R6/2 activity at 6 or 9 weeks (data not
shown).
Inclusion formation in the R6/2 brain is not modified by
reduction of REGg
Although reduction of REGg levels did not alter the beha-
vioural phenotype of R6/2, it remained a possibility that its
genetic reduction altered inclusion formation as a result of
differential processing of the R6/2 transprotein by REGg-
capped proteasomes. A similar effect has previously been
observed whereby early inclusion formation in R6/2 can be
modified by overexpression of Hsp70 without affecting the
Figure 2. REGg is highly expressed in the mouse brain and is restricted to neuronal nuclei. (A) Coronal sections through cortex of WT and REGg null mouse
brain reveal a predominant nuclear localization of REGg. The absence of any specific staining in the null mice confirms that REGg has been successfully
knocked out and that the antibody is specific. Arrow points to a nucleus expressing REGg, and inset shows higher magnification of another nucleus expressing
REGg. The nuclear counterstain is methyl green. (B) Western blot analysis on nuclear and cytoplasmic 12-week-old brain fractions confirms that REGg has a
nuclear localization. Blots were stained with histone H2B as a nuclear marker and b-actin as a cytoplasmic marker. (C) REGg colocalizes with the neuronal
marker NeuN in the mouse brain. No REGg was detected in glial cells. Ctx, cortex; cyt, cytoplasm and nuc, nucleus.
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behavioural phenotype (30). To address this issue, we adopted
a qualitative immunohistochemical approach, where we
compared inclusion formation in the CA1 region of the hippo-
campus. We chose this region as REGg is expressed there, and
it provides a precise location that allows a fair comparison of
inclusion formation between brains. From three brains of all
three genotypes, seven sections of each were stained in paral-
lel with S830 anti-huntingtin antibody, which can be used to
monitor inclusion formation in the R6/2 hippocampus (31).
We used 4-week-old brain sections because at this age,
inclusion formation is still at an early stage, allowing any
potential difference between REGg genotypes to be more
easily detected. Comparison of inclusion formation in R6/2
with reduced or knocked out REGg revealed no obvious
difference in overall size or amount of inclusions (Fig. 5).
We also compared inclusion formation qualitatively at 13
weeks and found no obvious differences caused by REGg
reduction (data not shown). This suggests that the association
of REGg with proteasomes does not affect the processing of
mutant polyglutamine and/or inclusion body formation in
R6/2 mice.
Core 20S proteasome activity is upregulated
in R6/2 brains
We next investigated core proteasome activity in whole brain
extracts of R6/2 and WT mice. This would highlight any
alteration of the UPS in the R6/2 brain at the level of
the 20S proteasome or its association with activators. We
measured the degradation of the fluorogenic peptide sLLVY-
MCA as a reliable reporter of proteasomal chymotrypsin-
like activity, but did not find substrates that were completely
specific for the trypsin-like or PGPH-like activities (data
not shown). We found that there was no difference in
chymotrypsin-like proteasome activity between R6/2 and
WT at 4 or 8 weeks regardless of REGg levels [e.g. no
Figure 3. Genetic reduction of REGg does not affect R6/2 rotarod performance, grip strength or failure to gain weight. Animal numbers were as follows. WT:
n ¼ 10, R6/2; REGgþ/þ: n ¼ 13, REGgn/þ: n ¼ 12, R6/2; REGgn/þ: n ¼ 12, REGgn/n: n ¼ 10, R6/2 and REGgn/n: n ¼ 10. Error bars represent standard errors of
the mean. (A) Rotarod performance of R6/2 mice is significantly lower than that of non-R6/2 from 4 weeks onwards and REGg has no effect on R6/2 perform-
ance. REGgn/n mice perform significantly worse than REGgn/þ or REGgþ/þ at 4 and 8 weeks, but not at 10 or 12 weeks. (B) Graph showing grip strength
performance of mice. R6/2 mice perform significantly worse than non-R6/2 at 12 weeks regardless of REGg levels. (C) Weight gain of R6/2 mice is significantly
lower than that of non-R6/2 mice. (D) Actual weight of mice shows that REGgn/n mice weigh significantly less than others until 9 weeks of age. Dips in weight
and weight gain observed at 8, 10 and 12 weeks can be attributed to weight loss as a result of rotarod exercise. P ¼ 0.036; P, 0.001.
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interaction between REGg and R6/2 genotypes at 4 weeks
(GLM ANOVA: F(1,39) ¼ 0.72, P ¼ 0.491)] (Fig. 6A).
Although the graph suggests that REGg depletion causes a
reduction in chymotrypsin-like activity, this falls just out of
significance (GLM ANOVA: F(1,39) ¼ 2.76, P ¼ 0.076).
Surprisingly, by 13 weeks, chymotrypsin-like activity was
significantly upregulated in R6/2 than in non-R6/2 (GLM
ANOVA: F(1,48)¼ 17.04, P , 0.001) (Fig. 6A), irrespective
of REGg levels.
Levels of various proteasomal proteins are unaltered
in R6/2 brains
To investigate the potential reasons for the upregulation
of 20S core activity in R6/2, we compared protein levels of
various proteasome or proteasome-associated subunits
between 12-week R6/2 and WT brains. We first looked for a
direct upregulation of 20S proteasome (32), but found no sig-
nificant upregulation in R6/2 corresponding to the increase in
20S activity (Fig. 6B). We also failed to find a difference in
levels of the 19S S10B subunit (33) in 12-week-old R6/2
brains (Fig. 6B). It has previously been reported that an upre-
gulation of proteasome activity in HD94 mice was linked to an
increase in the inducible immunoproteasome subunits LMP2
and LMP7 (16). However, the levels of these proteins were
not significantly different between R6/2 and WT mice at 12
weeks (Fig. 6B). Finally, because the association of protea-
somes with the 11S activators can markedly stimulate 20S
activity, we compared levels of the activator REGa between
R6/2 and WT brains, but found no significant difference
(Fig. 6B). Nor was there a difference in REGg levels
(Fig. 1). Therefore, we detected no upregulation of proteaso-
mal proteins, which may account for the increase in 20S
activities in R6/2.
Figure 4. Exploratory activity of 13-week-old mice displayed as 5 min moving averages. Activity cage data reveal an overall hypoactivity of R6/2 mice com-
pared to non-R6/2 for rearing (P, 0.001), activity (P ¼ 0.002), centre rearing (P ¼ 0.004) and mobility (P , 0.001). The reduction of REGg did not improve
the hypoactivity of R6/2.
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26S proteasome activity is unchanged in R6/2
Although we observed an upregulation of 20S activity in R6/2
than in WT, this did not exclude the possibility that there was
an impairment in 26S proteasome activity in the R6/2 brain.
To compare 26S proteasome activity between R6/2 and WT,
we measured the in vitro degradation of radiolabelled ubiqui-
tylated lysozyme by mouse whole brain extracts. This assay
would detect any impairment of R6/2 brain extracts in the
recognition of a ubiquitylated substrate, its unfolding by the
19S proteasome and subsequent degradation by the 20S
core. We found that there was no difference in 26S proteasome
activity between R6/2 and non-R6/2 at any timepoint (e.g.
13-week GLM ANOVA: F(1,48) ¼ 1.51, P ¼ 0.225) and
REGg genotype had no effect (Fig. 7). Therefore, we detected
no impairment of the 26S proteasome in the R6/2 brain.
DISCUSSION
We have recently hypothesized that the nuclear proteasome
activator REGg may contribute to pathogenesis in polygluta-
mine disease by preventing proteasomes from cleaving
within polyglutamine stretches (24). REGg is homologous to
the cytoplasmic proteasome activators, REGa and REGb,
which are involved in the generation of peptides for antigen
presentation. Proteasome activators can markedly increase
the in vitro degradation of small peptides specific for some
or all of the three proteasomal catalytic sites, possibly by con-
trolling the opening of proteasomal entry and exit gates
(reviewed in 34). It is unknown exactly how in vitro activation
properties are biologically relevant, but one possibility is that
proteasome activators bind to 26S proteasomes and thus alter
the proteasomal cleavage sites within ubiquitylated proteins.
Although REGa and REGb stimulate all three proteasome
catalytic sites in vitro, REGg has been shown to stimulate
only the trypsin-like site, but suppresses the activation of the
chymotrypsin-like and PGPH active sites (23). These are the
sites responsible for hydrolysing Gln–Gln bonds. In addition,
it is highly expressed in the brain and localized to the nucleus,
a major site of polyglutamine pathology. We hypothesized that
mutant proteins with a polyglutamine tract of over 40 repeats
may therefore become kinetically trapped inside proteasome
chambers capped with REGg, which would be consistent
with the finding that peptides greater than 40 residues are
rarely found in proteasomal digests.
In this study, we have rigorously tested this hypothesis. We
found that reducing or knocking out REGg protein levels did
not improve the behaviour of R6/2 mice, did not alter the
inclusion formation in the R6/2 brain and failed to affect
proteasome activities of R6/2. Interestingly, the rearing and
activity of R6/2 mice were moderately worsened in REGg
nulls at 13 weeks. However, as there was no consistent syner-
gism between R6/2 and REGg null mice, this is unlikely to
reflect a general beneficial role of REGg in R6/2 phenotype.
We therefore conclude that REGg is not a viable therapeutic
target in HD or other polyglutamine diseases.
There are two mechanisms through which mutant polyglu-
tamine tracts have been proposed to impair proteasome func-
tion. In the first, although unfolding and degradation of the
substrate are initiated, regions that are too tightly aggregated
to unfold would be too large to enter the 20S chamber (35).
In support of this, it has been shown by FRET and FLIP analy-
sis that proteasomes are in very close association with poly-
glutamine inclusions and have a slow off-rate, suggesting
that polyglutamines become irreversibly associated with
proteasomes at inclusion bodies (36). This is consistent with
the colocalization of proteasome components with inclusion
bodies in brain sections of patients and transgenic mice
(9,10,18). Alternatively, the failure of polyglutamine tracts
to be degraded by and exit from proteasomes may cause the
26S proteasome to become clogged (20,24,36). Therefore,
either the failure of aggregated polyglutamine proteins to
enter the proteasome or the proteasome clogging with
trapped polyglutamine may inhibit the proteasome from
degrading other substrates. However, contrary to these hypo-
theses, it has been shown in a cell culture system that impair-
ment of the UPS occurs in both the nucleus and the cytoplasm
regardless of which compartment the mutant polyglutamine is
restricted to (12). This suggests that the impairment of the
UPS can be caused by mechanisms other than an aberrant
association of polyglutamines with proteasomes.
If irreversible inhibition of proteasomes were a significant
factor throughout the R6/2 brain, we would have expected
to detect diminished 26S proteasome activity. However, we
Figure 5. Comparison of inclusion body formation in 4-week R6/2 mouse
brains that are REGgþ/þ, REGgn/þ or REGgn/n. The CA1 region of the hippo-
campus was used for comparison. No obvious difference was apparent in the
different genotypes. Insets show higher magnification of inclusion bodies.
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failed to detect lowered 26S activity and even observed a
marked increase in the hydrolysis of the proteasome-specific
sLLVY fluorogenic peptide. Therefore, although a degree of
proteasome clogging/blockage may indeed occur, the degrada-
tive capacity of the UPS is not compromised in R6/2 mice.
These results are consistent with other studies. For example,
no neuronal impairment was detected by a UPS reporter
with a UFD signal in SCA7 mice, suggesting that significant
proteasome impairment by polyglutamines is not a general
occurrence in vivo (14).
There is considerable evidence that modulating the UPS
alters inclusion body formation (19,37–40), but it is still
unknown whether, when and how the UPS contributes to poly-
glutamine pathogenesis in vivo. To date, there is considerable
evidence against a UPS impairment in polyglutamine disease
mouse models (14–16), and we find no evidence of an impair-
ment in R6/2 mice. In symptomatic HD patients, however, a
decrease in proteasome activity was observed at the level of
the 20S core (17). Therefore, there is a strong possibility that
rather than being a primary cause of toxicity, UPS dysfunction
may occur as a consequence of the disease or even by a syner-
gistic effect of polyglutamine stress and the normal human
ageing process. Indeed, Seo et al. (17) note that they found an
increase in 20S activity in the brain of a patient with juvenile
HD. This is comparable to the increased proteasome activity
in R6/2 and HD94 mice (16). Interestingly, they also find that
human HD fibroblasts have lost the ability to upregulate protea-
some activity in response to overexpression of the 11S activator
REGa. A similar effect has been reported elsewhere whereby
neurons expressing mutant polyglutamine fail to increase pro-
teasome activity in response to heat shock, whereas cells
expressing WT polyglutamine effectively increase activity in
response to heat shock (41). Therefore, it is conceivable that
the normal ageing process invokes a level of proteasome
activity in healthy neurons which HD neurons cannot reach,
resulting in the observed diminution.
Figure 6. 20S proteasome activity is upregulated in R6/2 mice regardless of REGg levels. (A) Chymotrypsin-like activity of mouse brain extracts is significantly
higher in 13-week R6/2 mouse brains when compared with non-R6/2 regardless of REGg levels. Error bars represent the standard error of the mean. (B) Western
blot of 12-week R6/2 and WT brain lysates showed no significant difference in levels of 20S proteasome, the 19S S10B subunit, LMP2, LMP7 or REGa.
a-tubulin was used as a loading control for all antibodies except the 20S antibody, where LDH was used.
40 Human Molecular Genetics, 2006, Vol. 15, No. 1
 at Periodicals D
ept on February 20, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
In order to try and account for the upregulation of protea-
some activity in R6/2 brains, we compared protein levels of
various proteasome-associated proteins of 12-week-old R6/2
and WT. We found that 20S proteasome levels were not sig-
nificantly upregulated in R6/2. However, we did observe
that there was in fact a minor but consistent increase in 20S
levels in R6/2 at 4, 8 and 13 weeks. Similarly, although
LMP7 levels were not significantly upregulated in R6/2, we
found that they did tend to be moderately higher from 4
weeks onwards. However, as these modest upregulations do
not correlate with the 20S activity increase, their relevance
is unclear. We also compared protein levels of the 19S
S10B subunit, the immunoproteasome subunit LMP2 and the
11S proteasome activators REGg and REGa, but found no
significant difference between R6/2 and WT. The upregulation
of activity in R6/2 mice therefore may be due to an altered
association of 20S core with regulators and other subunits,
rather than a direct upregulation of proteasomal proteins.
For example, it may be the case that although the
levels of immunoproteasome subunits LMP2 and LMP7 are
unaltered in R6/2, their incorporation into 20S proteasomes
may be increased. Similarly, proteasomes may be associated
with the REGa/b complex more frequently in R6/2 than in
WT, which again could account for increase in activities.
A major issue yet to be resolved is why there appears to be a
marked inhibition of the UPS in some cell models of poly-
glutamine disease (11–13), but strong evidence against an
inhibition in vivo (14). It could be argued that cell models
do not reflect disease pathology as accurately as mouse
models. However, an interesting possibility is that different
reporter degrons are differentially recognized in disease and
WT contexts. In this case, the impairment of the UPS in cell
models (11,13) would lie within the ubiquitylation machinery.
For example, the specific E2 ubiquitin conjugating enzymes
and the E3 ubiquitin ligases that recognize the degrons used
in these UPS reporters may be compromised, whereas those
that recognize N-end rule and UFD signals used in other
studies (8,14) may function to full capacity. In this case, an
impairment in the UPS would only affect a subset of protea-
some substrates which may or may not appreciably affect
the disease process. It will be important to test impairment
of the UPS in polyglutamine disease in vivo using a mouse
expressing a UPS reporter construct similar to that used by
Bence et al. (11). This will be important to determine defini-
tively whether UPS impairment can be a significant factor in
polyglutamine disease.
MATERIALS AND METHODS
Mouse husbandry and genotyping
Mice were housed, and experimental procedures were performed
according to the Home Office regulations. Mice had unlimited
access to water and number 3 rodent breeding chow (Special
Diet Services, Witham, UK) and were subject to a 12 h light
(08:00–20:00) and 12 h dark (20:00–08:00) cycles. Mice were
housed 5 to a cage with environmental enrichment in the form
of paper shred bedding (Enviro-dri, Lillico, Betchworth, UK),
a play tunnel (Datesand Ltd, Manchester, UK) and wood shav-
ings (GLP Aspen Chips, Datesand Ltd). The R6/2 mouse
colony was maintained by backcrossing R6/2 males to
(C57BL/6xCBA) F1 females (B6CBAF1/OlaHsd, Harlan Olac,
Bichester, UK). R6/2 mice were identified by polymerase
chain reaction (PCR) (29), and the CAG repeat size was deter-
mined as described previously (42). REGg knock-out mice
were generated as described previously (25) and maintained on
a C57/BL6 background. Mice were identified by PCR of tail-
tip DNA in a 25 ml reaction containing 1 ml DNA (100 ng/ml),
3 ml 2 nM dNTPs, 2.5 ml AM buffer [670 mM Tris, 166 mM
ammonium sulphate, 20 mM magnesium chloride, 1.7 mg/ml
bovine serum albumin (BSA), 0.1 M b-mercaptoethanol], 1 ml
forward primer ‘a’ TCGAGCGAGCACGTACT (100 ng/ml),
1 ml reverse primer CACGATGGACTGGATGGT (100 ng/
ml), 1 ml forward primer ‘b’ CTAACATAACTTACCTTGCC
(100 ng/ml), 0.2 ml Promega Taq (5 U/l) and 15.3 ml dH2O.
The reverse primer and forward primer ‘a’ or forward primer
‘b’ amplified mutant and WT bands, respectively. Cycling con-
ditions were 958C 120 s, 30 (958C 45 s, 508C 45 s and 728C
45 s) and 728C 7 min.
Behavioural analysis
Rotarod and grip strength analysis were performed as
described previously (29). Briefly, mice were placed on a
modified Ugo Basile 7650 accelerating RotaRod (Linton
Instrumentation, UK). At 4 weeks of age, mice were tested
on four consecutive days, with three trials per day. At 8, 10
and 12 weeks of age, mice were tested on three consecutive
days, with three trials per day. Grip strength was measured
as described previously, but using a digital grip strength
meter (San Diego Instruments). Mice were weighed weekly
to the nearest 0.1 g. Exploratory activity of mice was assessed
and statistics performed as recently described (43).
Figure 7. 26S proteasome activity of mouse brain extracts shows no difference
between R6/2 and WT brains at any timepoint. There is also no effect of redu-
cing REGg levels on 26S activity in mouse brains. Error bars represent stan-
dard errors of the mean.
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Western blot analysis
Mice were sacrificed by cervical dislocation, and brains were
quickly dissected and frozen in isopentane on dry ice. Half
brains from REGg mice were homogenized with a dounce
homogenizer in 1 ml sodium phosphate buffer [20 mM
sodium phosphate, 1% sodium dodecyl sulphate (SDS), 2 mM
phenylmethylsulphonyl fluoride (PMSF) and complete protease
inhibitors (Boehringer Mannheim)]. Half brains from R6/2 mice
were homogenized in 1% Triton X buffer [1% Triton X-100 in
phosphate-buffered saline (PBS) and complete protease inhibi-
tors (Boehringer Mannheim)] for blotting with REGa and
REGg or in sucrose buffer [0.25 M sucrose, 10 mM Tris pH 7
and complete protease inhibitors (Boehringer Mannheim)] for
all other antibodies. The protein concentration of the lysates
was adjusted to 5 mg/ml using the BCA assay kit (Perbio).
Lysates were aliquoted, snap frozen on dry ice and stored
at 2808C. Nuclear and cytoplasmic extracts were prepared as
described previously (30).
Lysates were thawed on ice before 10–30 mg protein was
boiled for 5 min and loaded onto 10% SDS–PAGE gels, sepa-
rated and blotted onto Protran membranes (Schleicher and
Schuell). Membranes were then blocked in 5% non-fat dried
milk (NFDM) for 1 h at room temperature and probed with
primary antibody in 5% NFDM for 2 h at room temperature
or overnight. For chemiluminescent detection, blots were
washed three times in Tris-buffered saline (TBS) and probed
with horseradish peroxidase (HRP)-linked secondary anti-
bodies in 5% NFDM for 1 h at room temperature. Protein
was detected by chemiluminescense (ECL kit, Amersham),
according to manufacturer’s instructions. For quantification
of REGg and REGa protein levels, blots were probed with
Alexa 488/546-attached secondary antibodies and incubated
for 1 h at room temperature, then washed three times with
TBS in darkness. Protein was detected on a Typhoon 9200
PhosphorImager (Amersham Biosciences), and band inten-
sities were calculated using ImageQuantw software
(Molecularw Dynamics). All other protein levels were quanti-
fied on a Bio-Rad GS-800 Calibrated Densitometer using
Quantity-Onew Software. At least four brains of each geno-
type were used for quantification. Primary antibodies and
dilutions were as follows: REGg (Transduction Laboratories)
(mAb, 1:1000), REGa (Affinity Bioreagents) (rabbit
pAb, 1:5000), b-actin (AbCam) (mAb, 1:10 000), a-tubulin
(Sigma-Aldridge) (mAb, 1:2000), LMP2 (Biomol) (rabbit
pAb, 1:2000), LMP7 (Biomol) (rabbit pAb, 1:10 000) and
19S S10B (33) (rabbit pAb, 1:5000). Our lactate dehydrogen-
ase (LDH) antibody was prepared in rabbits using purified
porcine lactate dehydrogenase (Calbiochem) as immunogen.
Immunoglobulins (IgG) were precipitated from serum with
50% ammonium sulphate, desalted and lyophilized. The resus-
pended IgG fraction, diluted 1:2000, detects an appropriately
sized band of 35 kDa. Secondary antibody dilutions were
HRP-linked anti-rabbit (Dako) (1:3000) and anti-mouse (Vec-
tastain) (1:5000); Alexa-488 conjugated anti-mouse (Mole-
cular Probes) (1:1000) and Alexa-546 conjugated anti-rabbit
(Molecular Probes) (1:1000).
Membranes were stripped by incubation in stripping buffer
(100 mM 3-mercaptoethanol, 2% SDS and 62.5 mM Tris–HCl
pH 6.7) for 20 min at 508C with occasional agitation.
Immunohistochemistry and confocal microscopy
Mouse brains were dissected and frozen as described earlier.
Sections were cut to a thickness of 15 mm using a cryostat
(Bright Instrument Co. Ltd, UK) and fixed in 4% paraformal-
dehyde for 30 min. Immunohistochemistry for light and confo-
cal microscopy was carried out as described previously (31).
Primary antibody dilutions were as follows: REGg (Biomol)
(rabbit pAb, 1:15 000), S830 (sheep pAb, 1:2000) and NeuN
(Chemicon) (mAb, 1:500). Biotinylated secondary antibodies
from Vector Laboratories were anti-rabbit (1:200) and
anti-sheep (1:500) and fluorescent secondary antibodies from
Molecular Probes were Alexa-488 anti-mouse (1:400) and
Alexa-546 anti-rabbit (1:400). Sections were viewed on a
Zeiss light microscope and images were captured using an
axiocam, with the help of the Zeiss axiovision software. For
colocalization, a Zeiss LSM150 confocal microscope was used.
20S and 26S proteasome assays
Frozen mouse brains were weighed, placed in a 10 ml glass
homogenizer and overlaid with 2.5 volumes of lysis buffer
(0.25 M sucrose, 10 mM Tris pH 7.0, complete protease inhibi-
tors). Brains were thawed in lysis buffer for 2 min, then homo-
genized with three passes of a teflon pestle driven by a hand
drill. Samples of whole cell extract were then aliquoted into
fractions that were either stored at 2808C (26S assays) or
kept on ice (20S assays). Protein concentration was deter-
mined in duplicate on fresh lysate using Coomassie Plus
Protein Assay Reagent (Pierce). Assays were performed in tri-
plicate on three brains of each genotype/timepoint. For each
assay, values for 1 min averages were calculated from each
reaction (i.e. at 3, 6 and 9 min), and the data pooled for
each genotype/timepoint before statistical analysis were
carried out (GLM ANOVA).
Assays for 20S proteasome activity were performed using
the sLLVY-MCA fluorescent peptide (Peptides International)
as a substrate. sLLVY was dissolved at 10 mM in DMSO and
diluted to a working stock of 200 mM in reticulocyte buffer
(10 mM Tris pH 7.8, 5 mM MgCl2, 10 mM KCl and 1 mM
DTT) prior to use. Reaction mixes (100 ml final volume)
were prepared in reticulocyte buffer and contained 10 mg of
protein, 2.5 ml of an ATP regenerating system (6 mg/ml
ATP, 1.2 mg/ml creatine kinase and 60 mg/ml phosphocrea-
tine) and 100 mM of fluorescent peptide substrate. Reactions
were incubated at 378C for 3, 6 and 9 min, quenched with
200 ml of 100% ethanol and read using a Perkin Elmer LS-5
Spectroflourimeter (380 nm excitation/440 nm).
Assays for 26S proteasome activity were performed using
iodinated ubiquitin–lysozyme conjugates as substrates. 125I-
lysozyme conjugates were prepared according to previously
published methods (44) and stored at 2808C. Reaction
mixes (100 ml final volume) were prepared in reticulocyte
buffer and contained 10 mg of protein, 2.5 ml of an ATP regene-
rating system and 50 ml of 125I-lysozyme conjugates. Reac-
tions were incubated at 378C for 3, 6 and 9 min, then
quenched by the addition of 800 ml of 1% BSA (dissolved
in 10 mM Tris pH 7.0) followed by 100 ml of 100% trichloro-
acetic acid. Samples were then mixed, incubated on ice for
15 min, centrifuged at 14 000g for 15 min and ultimately
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analysed on a Beckman Gamma 4000 counter. Both super-
natant (800 ml) and pellet were counted. To correct for the
amount of supernatant removed, supernatant counts were
divided by 0.8, and the corrected supernatant value was ulti-
mately divided by the total counts (soluble plus pellet). All
samples were corrected for background soluble counts found
in a zero control tube that did not contain brain lysate.
Control assays were performed on normal mouse brain
extracts to ensure the accuracy of the proteasome activity
measurements. Inhibitor studies demonstrated that both
Ub-conjugate (26S) and sLLVY (20S) degradation were
proteasome specific. sLLVY was most diagnostic of mouse
brain proteasome activity, as the proteasome inhibitors lacta-
cystin and epoxomicin inhibited its degradation by 80–90%
(data not shown). Epoxomicin inhibited Ub-conjugate degra-
dation by .80% (data not shown). We attempted to assay
the trypsin-like and caspase-like activities of the proteasome
using the fluorescent peptides LLR-MCA (Peptides Inter-
national) and LLE-bNA (Sigma). However, inhibitor controls
using epoxomicin and lactacystin indicated that their degra-
dation in mouse brain extracts was not highly proteasome
specific. Further control experiments were performed to
ensure that enzymatic measurements were in the linear
range, where both 20S and 26S enzyme activities were directly
proportional to the reaction time and the amount of extract in
the reaction mix (data not shown).
Statistics
GLM ANOVA and post hoc analysis were performed on
Excel and Minitab for behavioural and proteasome activity
assays. For western blot quantification, Student’s t-test was
performed.
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